Proteon Therapeutics Company Profile (NASDAQ:PRTO)

About Proteon Therapeutics

Proteon Therapeutics logoProteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company's product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PRTO
  • CUSIP:
Key Metrics:
  • Previous Close: $1.90
  • 50 Day Moving Average: $1.97
  • 200 Day Moving Average: $6.72
  • 52-Week Range: $1.75 - $11.63
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.10
  • P/E Growth: 0.00
  • Market Cap: $31.53M
  • Outstanding Shares: 16,594,000
  • Beta: 1.72
Profitability:
  • Return on Equity: -51.48%
  • Return on Assets: -47.65%
Debt:
  • Current Ratio: 9.86%
  • Quick Ratio: 9.86%
Additional Links:
Companies Related to Proteon Therapeutics:

Analyst Ratings

Consensus Ratings for Proteon Therapeutics (NASDAQ:PRTO) (?)
Ratings Breakdown: 6 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $15.71 (727.07% upside)

Analysts' Ratings History for Proteon Therapeutics (NASDAQ:PRTO)
Show:
DateFirmActionRatingPrice TargetDetails
1/17/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldView Rating Details
12/14/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details
12/14/2016Raymond James Financial, Inc.Reiterated RatingStrong-Buy -> Market PerformView Rating Details
12/14/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
12/14/2016Maxim GroupBoost Price TargetBuy$6.00 -> $19.00View Rating Details
12/14/2016Stifel NicolausDowngradeBuy -> Hold$19.00 -> $3.00View Rating Details
12/13/2016Robert W. BairdDowngradeOutperform -> Neutral$20.00 -> $3.00View Rating Details
9/22/2016HC WainwrightInitiated CoverageBuy$18.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Proteon Therapeutics (NASDAQ:PRTO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
11/7/2016Q3 2016($0.46)($0.43)ViewN/AView Earnings Details
5/9/2016Q1($0.41)($0.40)ViewN/AView Earnings Details
3/14/2016($0.34)($0.39)ViewN/AView Earnings Details
11/12/2015Q315($0.33)($0.33)ViewN/AView Earnings Details
8/13/2015Q215($0.30)($0.31)ViewN/AView Earnings Details
5/13/2015($0.24)($0.28)ViewN/AView Earnings Details
3/20/2015($0.26)($0.24)ViewN/AView Earnings Details
11/26/2014($0.31)($31.03)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Proteon Therapeutics (NASDAQ:PRTO)
Current Year EPS Consensus Estimate: $-1.76 EPS
Next Year EPS Consensus Estimate: $-1.72 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.42)($0.42)($0.42)
Q2 20161($0.43)($0.43)($0.43)
Q3 20161($0.46)($0.46)($0.46)
Q4 20161($0.47)($0.47)($0.47)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Proteon Therapeutics (NASDAQ:PRTO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Proteon Therapeutics (NASDAQ:PRTO)
Insider Ownership Percentage: 50.90%
Institutional Ownership Percentage: 49.28%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/6/2016George Arthur EldridgeCFOBuy4,000$5.78$23,120.00View SEC Filing  
12/1/2015Timothy P. NoyesCEOSell5,000$14.97$74,850.00View SEC Filing  
11/2/2015Timothy P. NoyesCEOSell5,000$13.50$67,500.00View SEC Filing  
10/1/2015Timothy P. NoyesCEOSell5,000$13.33$66,650.00View SEC Filing  
9/8/2015Timothy P. NoyesCEOSell5,000$13.55$67,750.00View SEC Filing  
7/7/2015Daniel Philip GottliebVPSell1,965$16.86$33,129.90View SEC Filing  
10/27/2014James E FlynnInsiderBuy691,713$10.00$6,917,130.00View SEC Filing  
10/27/2014Skyline Venture Partners QualiMajor ShareholderSell56,038$10.00$560,380.00View SEC Filing  
10/27/2014Timothy HainesDirectorBuy950,000$10.00$9,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Proteon Therapeutics (NASDAQ:PRTO)
DateHeadline
News IconSell-side is Weighing in on Proteon Therapeutics, Inc. (NASDAQ:PRTO) Earnings - Aiken Advocate (NASDAQ:PRTO)
aikenadvocate.com - February 22 at 7:29 PM
News IconProteon Therapeutics, Inc. (NASDAQ:PRTO) Price Target & Stock Check - Rockville Register (NASDAQ:PRTO)
rockvilleregister.com - February 15 at 4:53 AM
finance.yahoo.com logoProteon Therapeutics Announces Two Presentations at the American Society of Diagnostic and Interventional Nephrology Meeting (NASDAQ:PRTO)
finance.yahoo.com - February 14 at 5:21 AM
News IconTrading Spotlight: Zooming in on Shares of Proteon Therapeutics Inc. (PRTO) - Davidson Register (NASDAQ:PRTO)
davidsonregister.com - February 11 at 2:31 AM
streetinsider.com logoProteon Therapeutics (PRTO) Announces Two Presentations at ASDIN Meeting (NASDAQ:PRTO)
www.streetinsider.com - February 6 at 7:26 PM
investing.com logoPRTO Stock Is Worst Performer On NASDAQ (NASDAQ:PRTO)
www.investing.com - December 14 at 8:09 PM
rttnews.com logoProteon Therapeutics Inc. (PRTN) Has Plunged To A New Low After Study Failed (NASDAQ:PRTO)
www.rttnews.com - December 14 at 8:09 PM
News IconProteon Therapeutics (PRTO) Crashes on Trial Results; Upside Visualized in Achaogen (AKAO) (NASDAQ:PRTO)
vouxmagazine.com - December 14 at 8:09 PM
marketexclusive.com logoProteon Therapeutics Inc (NASDAQ:PRTO)’s Miss, And Resulting Hit, Might Be An Opportunity (NASDAQ:PRTO)
marketexclusive.com - December 14 at 8:09 PM
smarteranalyst.com logoCowen Heads to Sidelines on Proteon Therapeutics Inc (PRTO) Following Clinical Trial Setback (NASDAQ:PRTO)
www.smarteranalyst.com - December 14 at 8:09 PM
bizjournals.com logoFailure in late clinical trial pummels Proteon Therapeutics stock (NASDAQ:PRTO)
www.bizjournals.com - December 14 at 8:09 PM
finance.yahoo.com logoProteon Slips to 52-Week Low on Kidney Disease Study Data (NASDAQ:PRTO)
finance.yahoo.com - December 14 at 8:22 AM
us.rd.yahoo.com logo7:00 am Proteon Therapeutics announces that its first Phase 3 clinical trial with investigational vonapanitase did not meet its primary endpoint of improved primary unassisted patency compared to placebo (shares halted) (NASDAQ:PRTO)
us.rd.yahoo.com - December 13 at 7:43 PM
bizjournals.com logoWaltham biotech's shares tank after kidney disease drug flunks trial (NASDAQ:PRTO)
us.rd.yahoo.com - December 13 at 7:43 PM
us.rd.yahoo.com logoProteon Therapeutics downgraded by Robert W. Baird (NASDAQ:PRTO)
us.rd.yahoo.com - December 13 at 7:43 PM
finance.yahoo.com logoProteon Therapeutics Craters on Missed Late-Stage Results (NASDAQ:PRTO)
finance.yahoo.com - December 13 at 7:43 PM
nasdaq.com logoProteon Therapeutics Announces Top-Line Data from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with CKD (NASDAQ:PRTO)
www.nasdaq.com - December 13 at 8:41 AM
finance.yahoo.com logoProteon Therapeutics kidney drug fails key study (NASDAQ:PRTO)
finance.yahoo.com - December 13 at 8:41 AM
marketwatch.com logoProteon Therapeutics' stock plummets after failed trial of kidney disease treatment (NASDAQ:PRTO)
www.marketwatch.com - December 13 at 8:41 AM
capitalcube.com logoProteon Therapeutics, Inc. :PRTO-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016 (NASDAQ:PRTO)
www.capitalcube.com - November 29 at 2:00 PM
News IconProteon Therapeutics, Inc. PRTO Financial and Strategic SWOT Analysis Review Prices from USD $300 (NASDAQ:PRTO)
www.bioportfolio.com - November 20 at 11:06 AM
publicnow.com logoProteon Therapeutics Announces First Patient Dosed in Phase 1 Study Evaluating Vonapanitase for the Treatment of Peripheral Artery Disease Below the Knee (NASDAQ:PRTO)
www.publicnow.com - November 10 at 10:06 AM
publicnow.com logoProteon Therapeutics to Participate in Two Upcoming Investor Conferences (NASDAQ:PRTO)
www.publicnow.com - November 9 at 6:55 PM
finance.yahoo.com logo8:23 am Proteon Therapeutics reports Q3 results; beats by $0.04; provides a cash balance & milestone update (NASDAQ:PRTO)
finance.yahoo.com - November 7 at 10:50 AM
finance.yahoo.com logoProteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference (NASDAQ:PRTO)
finance.yahoo.com - October 25 at 12:01 PM
4-traders.com logoProteon Therapeutics : Appoints Paul Hastings Chairman of Its Board of Directors (NASDAQ:PRTO)
www.4-traders.com - October 21 at 6:55 PM
4-traders.com logoProteon Therapeutics : to Present at Two Upcoming Investor Conferences (NASDAQ:PRTO)
www.4-traders.com - September 24 at 11:16 AM
publicnow.com logoProteon Therapeutics to Present at Two Upcoming Investor Conferences (NASDAQ:PRTO)
www.publicnow.com - September 1 at 10:00 AM
globenewswire.com logoProteon Therapeutics Announces Second Quarter 2016 Financial Results (NASDAQ:PRTO)
globenewswire.com - August 8 at 7:11 PM
sg.finance.yahoo.com logoProteon Therapeutics reports 2Q loss (NASDAQ:PRTO)
sg.finance.yahoo.com - August 8 at 11:40 AM
thestreet.com logo7 Stocks Under $10 to Trade for Big Post-Brexit Gains (NASDAQ:PRTO)
www.thestreet.com - August 3 at 10:11 AM
seekingalpha.com logoHave You Ever Heard Of Proteon Therapeutics? (NASDAQ:PRTO)
seekingalpha.com - July 19 at 7:05 PM
finance.yahoo.com logoProteon Therapeutics (PRTO) in Focus: Stock Gains 6.4% (NASDAQ:PRTO)
finance.yahoo.com - June 24 at 8:45 AM
publicnow.com logoProteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 22nd (NASDAQ:PRTO)
www.publicnow.com - June 15 at 8:29 AM
biz.yahoo.com logoPROTEON THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:PRTO)
biz.yahoo.com - June 13 at 8:01 AM
capitalcube.com logoProteon Therapeutics, Inc. :PRTO-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 (NASDAQ:PRTO)
www.capitalcube.com - June 8 at 6:07 PM
sg.finance.yahoo.com logoProteon Therapeutics reports 1Q loss (NASDAQ:PRTO)
sg.finance.yahoo.com - May 9 at 8:28 AM
publicnow.com logoProteon Therapeutics Announces First Quarter 2016 Financial Results (NASDAQ:PRTO)
www.publicnow.com - May 9 at 8:18 AM
biz.yahoo.com logoPROTEON THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:PRTO)
biz.yahoo.com - May 9 at 8:02 AM
publicnow.com logoProteon Therapeutics Announces Survey Findings Demonstrating Impact of Vascular Access Failure on Hemodialysis Patients (NASDAQ:PRTO)
www.publicnow.com - April 28 at 7:22 AM
finance.yahoo.com logoCoverage initiated on Proteon Therapeutics by Robert W. Baird (NASDAQ:PRTO)
finance.yahoo.com - April 14 at 5:41 AM
feeds.benzinga.com logoProteon Therapeutics Reports Publication of Promising Nonclinical Results from Vonapanitase in Peripheral Artery Disease (NASDAQ:PRTO)
feeds.benzinga.com - April 13 at 9:33 AM
publicnow.com logoProteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease (NASDAQ:PRTO)
www.publicnow.com - April 13 at 8:24 AM
sg.finance.yahoo.com logoProteon Therapeutics reports 4Q loss (NASDAQ:PRTO)
sg.finance.yahoo.com - March 14 at 8:57 AM
finance.yahoo.com logoProteon Therapeutics Announces Fourth Quarter and Full-Year 2015 Financial Results (NASDAQ:PRTO)
finance.yahoo.com - March 14 at 8:30 AM
finance.yahoo.com logoProteon Therapeutics to Present at the 2016 BIO CEO & Investor Conference February 8th (NASDAQ:PRTO)
finance.yahoo.com - February 2 at 8:00 AM
biz.yahoo.com logoPROTEON THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:PRTO)
biz.yahoo.com - January 22 at 8:31 AM
finance.yahoo.com logoProteon Therapeutics Completes Enrollment in PATENCY-1, First Phase 3 Clinical Study of Investigational Vonapanitase (NASDAQ:PRTO)
finance.yahoo.com - November 2 at 4:15 PM
finance.yahoo.com logoProteon Therapeutics to Present at the BIO-Europe 2015 Conference November 3 (NASDAQ:PRTO)
finance.yahoo.com - October 28 at 5:00 PM
noodls.com logoProteon Therapeutics Appoints Tony Kingsley to Its Board of Directors (NASDAQ:PRTO)
www.noodls.com - October 19 at 8:31 AM

Social

What is Proteon Therapeutics' stock symbol?

Proteon Therapeutics trades on the NASDAQ under the ticker symbol "PRTO."

Where is Proteon Therapeutics' stock going? Where will Proteon Therapeutics' stock price be in 2017?

8 analysts have issued 1-year price objectives for Proteon Therapeutics' shares. Their forecasts range from $3.00 to $27.00. On average, they anticipate Proteon Therapeutics' stock price to reach $15.71 in the next year.

When will Proteon Therapeutics announce their earnings?

Proteon Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

Who owns Proteon Therapeutics stock?

Proteon Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Deerfield Management Co. (8.03%), Pharmstandard International S.A. (7.02%) and Perceptive Advisors LLC (2.01%). Company insiders that own Proteon Therapeutics stock include Daniel Philip Gottlieb, George Arthur Eldridge and Timothy P Noyes.

Who sold Proteon Therapeutics stock? Who is selling Proteon Therapeutics stock?

Proteon Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Co..

Who bought Proteon Therapeutics stock? Who is buying Proteon Therapeutics stock?

Proteon Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Pharmstandard International S.A. and Perceptive Advisors LLC.

How do I buy Proteon Therapeutics stock?

Shares of Proteon Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Proteon Therapeutics stock cost?

One share of Proteon Therapeutics stock can currently be purchased for approximately $1.90.

Proteon Therapeutics (NASDAQ:PRTO) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Proteon Therapeutics (NASDAQ:PRTO)

Earnings History Chart

Earnings by Quarter for Proteon Therapeutics (NASDAQ:PRTO)

Dividend History Chart

Dividend Payments by Quarter for Proteon Therapeutics (NASDAQ:PRTO)

Last Updated on 2/23/2017 by MarketBeat.com Staff